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abstract
PURPOSE To understand readiness measures taken by oncologists to protect patients and health care workers
from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.
METHODS An online survey was conducted between March 24 and April 29, 2020.
RESULTS A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68
years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an
outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which
surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters,
was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse
transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% re-
ported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in
all patients. The most significant factors influencing an oncologist’s decision making regarding choice of
systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal
treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and
immune therapies were perceived as being less safe or unsafe by participants. The vast majority of par-
ticipants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors,
and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected,
most of the participants stated that they would be more hesitant to recommend second- or third-line therapies
in metastatic disease.
CONCLUSION Decision making by oncologists has been significantly influenced by the ongoing COVID-19
pandemic.
JCO Global Oncol 6:1248-1257. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) viral pandemic has affected nearly all
sectors of health care globally.1,2 As of June 17, 2020,
. 8.2 million people have been diagnosed with the
novel coronavirus (COVID-19), and 430,000 have died
as a result of the disease worldwide.3
COVID-19 has had a large and negative impact on
cancer treatment and research.5,6 There is significant
concern that the pandemic could lead to adverse
outcomes related to other preexisting conditions, in-
cluding cancer. This concern is driven by the potential
for delayed presentation, diagnosis, and/or treatment
that could emanate from patient avoidance of hospital
visits, doctors’ assumptions about the risk/benefit ratio
of every intervention, as well as health care resource
reallocation to patients with COVID-19.6-12 In addition,
COVID-19 has already had an impact on cancer
research.
Patients with cancer are considered to be at increased
risk from COVID-19–related complications because of
treatment-related immunosuppression, increased
comorbidities, and the underlying malignancy itself.9,13-19
In addition, they may be more likely to contract COVID-
19 secondary to frequent contact with the health
system and a high-risk environment for COVID
transmission.20,21 Organizations such as the European
Society for Medical Oncology (ESMO), ASCO, The
National Comprehensive Cancer Network, and the
American Association for Cancer Research (AACR)
have published guidelines regarding the precautions
and treatment modifications during the pandemic.22-26
We must carefully weigh the uncertainty from the
additional risk of infection versus benefit from treat-
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resulting from various oncological scenarios as well as the
variety of anticancer strategies, we do not have adequate
knowledge on the long-term impact of current changes in
oncologic practice.26-28
In this international, web-based survey, oncologists were
asked about pandemic-related changes in their clinical
practices and personal measures taken to protect their own
physical well-being in response to the COVID-19 pandemic.
METHODS
Study Design
We conducted a global survey of medical oncologists.
Respondents were contacted through differing distribution
channels, including direct e-mail and social media net-
works such as Twitter and oncology-specific groups on
Facebook. The survey was conducted between March 24
and April 29, 2020. Data collected included demographics,
country, practice setting, and years of experience. In ad-
dition, the survey tool included questions regarding atti-
tudes of medical oncologists around patient risk factors
(age, performance status, comorbidities), administration of
types of antineoplastic therapy (cytotoxic therapy, targeted
therapy, immunotherapy), and use of therapy in differing
settings (neoadjuvant, adjuvant vmetastatic). The question
“Do you perform COVID-19 RT-PCR test before the treat-
ment” was added to the questionnaire on April 11, 2020.
All the data in this survey are collected anonymously, with no
personal information (apart from their name and publicly




The frequencies of all categorical data were calculated. Bar
plots and stacked bar plots were used to visualize the data.
All statistical analyses were carried out using SPSS version
21.0 (SSPS, Chicago, IL).
RESULTS
Participant Demographics
A total of 343 oncologists from 28 countries participated in
the survey, and 95% of responses were received between
April 1 and April 29, 2020. The median age of the par-
ticipants was 43 years (range, 29-68 years), and the ma-
jority were male (62%). At the time of the survey, almost all
participants stated that there was an outbreak in their
country (99.7%). Most of the participants practiced at
a university or academic center (71%) and have. 10 years
of experience in practice (65%; Tables 1 and 2).
Readiness Measures
Overall, 43% of participants cared for ≥ 20 patients daily
during the pandemic, and 16% saw ≥ 35 patients. The use
of telemedicine among the participants was quite common
(80%). All participants stated that they were consistently
using personal protective equipment (PPE), of which
surgical mask (90%), gloves (52%), and glasses (39%)
were most frequently used. N95 mask usage rate was
found to be 33% (Fig 1). Because the question “Do you
perform COVID-19 RT-PCR test before the treatment” was
added to the questionnaire after the initial inception of the
questionnaire, only 266 answers were received. Although
58% stated that they did not perform routine testing,
39% stated that they performed reverse-transcriptase po-
lymerase chain reaction (RT-PCR) tests in selected patients
and 3% in all patients.
Participant Attitudes
When asked about factors affecting treatment decision
making, participants stated patient age and concomitant
diseases were influential factors (81% and 92%, re-
spectively; Fig 2). Regarding perceptions about the safety
of antineoplastic therapy, hormonal treatments and tyro-
sine kinase inhibitors (TKIs) were considered to be relatively
safe, but cytotoxic chemotherapy and immune therapies
CONTEXT
Key Objective
Does COVID-19 influence the decision-making process of oncologists?
Knowledge Generated
In this international survey including 343 oncologists from 28 countries, the most commonly used personal protective
equipment was the surgical mask. Telemedicine is being increasingly used. The most significant factors influencing an
oncologist’s decision making regarding the determination of treatment were patient age and comorbidities. Hormonal
treatments and tyrosine kinase inhibitors were considered to be relatively safe, but cytotoxic and immune therapies were
perceived as being less safe or unsafe by respondents. Likewise, neoadjuvant, adjuvant, and first-line metastatic disease
was less affected, but most of the participants stated that they would be more reluctant to recommend second- or third-line
therapies in the metastatic setting
Relevance
During the pandemic, the decision-making process of oncologists is significantly affected. International collaboration and
prospective studies are critical in providing a stronger evidentiary basis for making these decisions.
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were considered less safe or unsafe (Fig 3). Most partici-
pants stated that during the pandemic they would use less
chemotherapy, anti–CTLA-4 antibody, anti–PD-1 or PD-L1
antibodies, and corticosteroids. However, participants did
not express alterations in prescribing patterns for hormonal
therapies, TKIs, and bone-modifying agents (Fig 4). A total
of 78% of the participants stated that they would use
granulocyte colony-stimulating factor (G-CSF) more
frequently.
In general, the decision to reduce use across all therapy
categories was expressed by participants. The degree of
therapy reductions was less pronounced for use of therapy
in the neoadjuvant and adjuvant setting. Second- and third-
line treatment use for metastatic disease was dramatically
reduced across survey participants (Fig 5).
We asked participants whether they would modify systemic
treatment dosing, schedules, and context of use (Figs 6
and 7). No significant differences in demographic, pre-
ventive, or practice-related data were seen among partic-
ipants of different nationalities.
DISCUSSION
The COVID-19 pandemic has resulted in changes in the
delivery of cancer care.16,17,24,26,27,29-31 Since its emer-
gence, COVID-19 has rapidly crossed all borders and af-
fected health care networks globally. Health care systems
and medical professionals have been propelled to respond
to the evolving and complex situation, with some of them
being rapidly overwhelmed by a sudden high number of
cases requiring health care resource reallocation. Given
early data suggesting that patients with cancer may be at
substantially higher risk of COVID-19–related complica-
tions, medical oncologists face unique challenges in
continuing to meet the needs of both patients and staff
during this unprecedented pandemic. This survey provides
important context of the readiness measures and per-
ceptions of medical oncologists during the initial stages of
the pandemic.
Our results demonstrate that, although oncologists are
trying to continue treating their patients on the basis of
guidelines, despite the lack of evidence regarding COVID-
19–related risk at the time of this study, they have made
important modifications in usual practice. Although neo-
adjuvant and adjuvant treatments in curative settings are
less affected, a decrease in treatment of metastatic disease
is expected based on our survey. Hormonal treatments are
generally considered safer, and there is no anticipated
change in delivery of these therapies. On the other hand,
there is no consensus about the safety of monoclonal
antibodies and immunotherapies among oncologists sur-
veyed. Although most recent data suggest that giving im-
mune checkpoint inhibitors (ICIs) to COVID-19–positive
patients with cancer is safe,8,18,32 it is highly probable that
the oncological community has acted with caution and
reserve regarding initiation or maintenance of such treat-
ments during the last months, potentially affecting patient
outcomes.
Telemedicine has been implemented at a low rate over the
decade, but it has become increasingly useful while mo-
bility is reduced and social distancing is mandated for
pandemic control.33,34 In our survey, 80% of the partici-
pants stated that they used telemedicine in some form
TABLE 1. Baseline Characteristics (N = 343)
Characteristic Measure




Prefer to self-describe/Prefer not to say 1 (3)
Primary place of work?
General hospital 16 (55)
University hospital/academic center 71 (244)
Private practice 13 (43)
Clinic in a rural setting , 1 (1)
Years in practice
, 10 35 (119)
11-20 44 (152)
. 20 21 (72)
No. of patients with cancer seen daily
, 10 16 (56)
11-20 41 (142)
21-35 27 (92)








Probably not 3 (9)
Definitely not 1 (1)
COVID-19 RT-PCR test before treatmenta
No 58 (155)
Yes, selected patients 39 (104)
Yes, all patients 3 (7)
Use of G-CSF
More than before 78 (267)
No change 22 (76)
NOTE. Data are presented as % (No.) or median (range).
Abbreviations: G-CSF, granulocyte colony-stimulating factor; RT-PCR, reverse-
transcriptase polymerase chain reaction.
an = 266 responses available for this variable.
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during this pandemic. However, the adaptation of the legal
infrastructure and reimbursement systems for telemedicine
are still ongoing. In addition, it is necessary to keep in mind
some difficulties. Limited use of phones, smartphones, or
internet access may be a barrier, especially in rural areas,
as well as for elderly patients. We will need to develop
strategies to overcome these issues with care delivery.
SARS-CoV-2 is a highly transmissible virus, and health care
professionals have been at the forefront of workers with the
highest risk of infection. Recently, the Infectious Diseases
Society of America published a guideline on PPE that
should be used for the protection of health care workers.35
The vast majority of survey participants stated that they
used surgical masks. Although only 32% of respondents
described using N95 masks, the survey did not capture the
proportion of respondents who had access to N95 masks
while caring for patients known to have COVID-19, which is
recommended, especially while doing invasive procedures
such as intubation, bronchoscopy, and any airway-related
manipulations.36 Unfortunately, severe shortages of PPE
globally have created significant challenges.35,37
A significant proportion of patients with COVID-19 are
asymptomatic, increasing the risk of recommending active
cancer treatment during the pandemic.38-40 Furthermore,
the PCR-based test used for the diagnosis of COVID-19 is
currently of suboptimal accuracy; in some cases where
radiologic COVID-19 is considered, the PCR test may be
negative.41 However, there is no recommendation as to
whether routine PCR testing should be required. Testing
availability and defining populations in which screening
tests should be performed for asymptomatic patients and
diagnostic tests for symptomatic patients remains a chal-
lenge globally. Also, developing workflows to operationalize
testing in a safe manner for patients and health care works
will be critical in mitigating viral spread.
The case fatality rate increases in the elderly population and
in patients with comorbidities such as diabetes mellitus,
hypertension, and cancer.2,10,13,20,27,42-44 However, current
data regarding cancer and COVID-19 remain elusive. In
a recent meta-analysis by Desai et al,45 the overall pooled
prevalence of cancer in patients with COVID-19 was 2.0%,
suggesting at least a doubling of the risk compared with the
general population. Given the heterogeneity present among
oncology patients, population-based estimates may not
estimate an individual’s risk. When making treatment de-
cisions in patients with cancer, oncologists consider a pa-
tient’s age, performance status, and concomitant diseases,
among many factors. This individualized approach will be
central to carefully evaluating the risk/benefit profile of
anticancer treatments during the pandemic. In our study,
80% of participants stated that age would affect their
treatment decisions, and 90% stated that the presence of
concomitant diseases would do so. Considered together,
age, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ≥ 2, or the presence of chronic obstructive
pulmonary disease (COPD) influenced . 80% of the
participants’ treatment decisions.
TABLE 2. Participant Countries


























United Arab Emirates 2 0.58
United Kingdom 33 9.62

















































FIG 1. Respondent answers to “What precautions are you taking for
yourself during clinical practice?”
Impact of COVID-19 on Oncologists’ Decision Making in Cancer
JCO Global Oncology 1251
Conventionally, curative cancer treatment often involves
neoadjuvant and/or adjuvant systemic treatment. Although
there is a modest decrease in the use of neoadjuvant
therapy compared with the prepandemic period—which
may correspond to a delay from some surgical interventions
during the pandemic—and a marked 50% reduction in
adjuvant treatment use, treatment practices are being
carried out with relative preservation of dose density and
intensity in the curative setting. For patients with metastatic
disease, 60% of the participants stated that they would offer
first-line treatment less frequently, and in case of systemic
treatments, 80% of the participants stated that they would
decrease the number of cycles of chemotherapy to
be given.
During the pandemic, it is perceived as essential to ad-
minister curative treatments asmuch as possible. However,
in the case of treatment regimens for which the incremental
benefits are low and the risk of infection is high, such as
second- and third-line therapy for metastatic disease, it
sounds more reasonable to colleagues to curtail use to
maximize survival in a patient population that may be
more debilitated at baseline. Largely, these decisions are
highly individualizing. It has become a priority to discuss
and refine the multiplicity of parameters for decision
making within our community as well as with the patients.
The magnitude of expected clinical benefit should be
evaluated for each intervention. Although some groups
have attempted to develop standardized guidelines, these
are not evidence based, given the unprecedented nature
of the pandemic. Such evidence-based statements will
need multivariable analyses of extremely large numbers of
patients with cancer.
Interestingly, hormonal treatments are generally consid-
ered safe. Because there are sex differences in suscepti-
bility and vulnerability to COVID-19, several hypotheses
related to the androgen pathway have been proposed.
Two different studies suggest that the use of antiandrogens
may be protective for COVID-19 in patients with prostate
cancer.46,47 In this survey, a significant part of the par-
ticipants (96%) stated that they considered hormonal
treatments safe.
Immunotherapy has rapidly become part of the standard
treatment protocols for many cancers, including mela-
noma, lung, kidney, and bladder. However, ICIs can cause
severe immune-mediated toxicity, such as pneumonitis,
colitis, hepatitis, and endocrine disorders.48 Because
management of ICI toxicity rarely requires the use of im-
munosuppressive steroids, we see some reluctance among
clinicians to prescribe ICIs during the COVID-19 pandemic.
There is concern that ICIs can increase the severity of the
disease because of their immunomodulatory properties.42
Although almost half of the participants were reticent about
whether they were safe or not, one-third of them stated that
they did not think it was safe. However, there is currently
paucity of data regarding ICIs and COVID-19. The 2020
AACR national meeting featured COVID-19 and cancer
special sessions. Data presented by Barlesi et al19 from 137
patients with cancer and COVID-19 who were treated at
Gustave Roussy showed that an ECOG performance status
. 1, hematologic malignancies, and chemotherapy within
the past 3 months were associated with worse outcomes;
however, immunotherapy or targeted agents in the past
3 months did not associate with the deterioration of the





































































FIG 2. Respondent answers to “Which comorbidities do you think
affect your treatment decisions?” COPD, chronic obstructive pulmo-





































































FIG 3. Respondent answers to “During the COVID-19 outbreak, do
you think the following treatments are safe?” BMA, bone-modifying
agents; TKI, tyrosine kinase inhibitor.
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Robilotti et al49 recently presented results of 423 patients
with cancer and COVID-19 disease from Memorial Sloan
Kettering Cancer Center (MSKCC). In the study, being
. 65 years of age and undergoing treatment with ICIs within
90 days were predictors for hospitalization and severe
disease. However, in a recent study, which was also from
MSKCC, including 69 patients with COVID-19 and lung
cancer, PD-1 blockade was not associated with the severity of
COVID-19.32 The US Food and Drug Administration has
approved doses of nivolumab administered every 4 weeks and
pembrolizumab every 6 weeks. This will be more convenient
in terms of reducing the frequency of patients coming to the
hospital. In the study presented by Zhang et al,14 having
cancer treatment in the last 14 days was found to be asso-
ciated with a more serious clinical course of COVID-19. In the
follow-up of 124 patients who received ICIs, only 1 patient had
COVID-19, and their clinical course was mild. In another
recently published large cohort study from China, hematologic
malignancy, lung cancer, or metastatic cancer (stage IV) were
associated with increased frequency of severe events. There
were no differences regarding the severity of COVID-19 be-
tweenpatients with nonmetastatic cancer andpatients without
cancer.17 The first results of the TERAVOLT (Thoracic Cancers
International COVID-19 Collaboration) were also presented
during AACR 2020. Data from 200 patients with thoracic
cancer were examined, revealing that the presence of COPD
was associated with hospitalization andmultiple comorbidities
associatedwith hospitalization and death risk. However, tumor
type and cancer therapy did not affect survival.15
In our survey, 80% of oncologists stated that they used
more G-CSF than before. Using G-CSF can protect patients
from hospitalization through reducing the risk of neu-
tropenic fever. Patients who required intensive care unit
admission because of COVID-19 showed a higher per-
centage of GM-CSF+ CD4+ T cells, suggesting excessive
activation of the immune response by G-CSF may promote































































FIG 4. Respondent answers to “Comparing with your previous
practice would you recommend the following treatments during the
COVID-19 outbreak?” BMA, bone-modifying agents; TKI, tyrosine
kinase inhibitor.



































































































FIG 5. Respondent answers to “Comparing with your previous practice
would you change your treatment algorithms for the following settings


































































FIG 6. Respondent answers to “Comparing with your previous practice
would you change dose density for the following settings during the
COVID-19 outbreak?” ICI, immune checkpoint inhibitor; TKI, tyrosine
kinase inhibitor.
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the development of lung injury.50 Therefore, although G-CSF
may reduce hospitalization from neutropenic complications,
it carries a theoretical risk of promoting pulmonary injury and
aggravating the COVID-19 course.22,50 Given the absence of
clinical data to resolve this, evidence is needed to clarify how
GM-CSF modulates the global risk of patients.
Our study has several limitations. The limited number and
format of questions does not provide an in-depth quan-
titative analysis of some common clinical practices.
However, we expected the brevity would increase re-
sponse rate and reliability. In addition, we cannot confirm
that all participants were medical oncologists, and al-
though conducted globally, the survey does not evenly
represent all countries This report serves as a pilot study to
learn general approaches and immediate reactions of
oncologists at this point in the COVID-19 pandemic and to
identify difficulties and uncertainties in clinical decision
making that would benefit from clearer guidance on the
basis of reliable data.
Many uncertainties exist with regard to COVID-19 and in-
fection in patients with cancer. The risk/benefit ratio of the
decisions we make and the expected benefit of everything
we do have become essential arguments and limiting
factors at the time of COVID-19. Counterintuitively, the
absolute benefit of an adjuvant therapy can sometimes be
modest in a curative setting, while it can be major in some
metastatic cancers where the palliative versus curative
impact of immunotherapy can be disputed. Ongoing re-
search is essential to improve our understanding of the
disease and optimize health care delivery strategies for
patients with cancer. This survey provides an important
context to assess current physician readiness and attitudes
about care delivery during the pandemic. The COVID-19
pandemic has affected, and continues to affect, both pa-
tients and oncologists in a variety of ways. As in all onco-
logical practice, it is critical that each patient be evaluated
on an individual basis, and the risk/benefit ratio of any
proposed therapy must be evaluated by a patient’s treating
oncologist.28 Although ESMO and ASCO have published
general guidelines to oncological practice, it is impossible to
provide recommendations for each clinical scenario.51 For
this reason, it is more important than ever that colleagues
continue to systematically discuss their patients in tumor
board settings. In addition, it is essential that the oncology
community gather comprehensive, rigorous data to further
improve the clinical decision-making process during this
unprecedented moment.52 The COVID-19 and Cancer
Consortium, a multicenter, voluntary registry collecting and
examining data on risk factors and outcomes of patients
with cancer who develop COVID-19, will play an important
role in understanding how baseline characteristics and
systemic treatment modalities affect the risk of severe
COVID-19.29,30 We hope, as our experience, collaboration,
and knowledge sharing improve, that we will be able to
more effectively manage this outbreak with more evidence-
based interventions and treatments.
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FIG 7. Respondent answers to “Comparing with your previous practice
would you change dose intensity for the following settings during the
COVID-19 outbreak?” ICI, immune checkpoint inhibitor; TKI, tyrosine
kinase inhibitor.
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Daniel Castellano, Saadettin Kılıçkap, Gilberto Morgan, Toni K. Choueiri
Collection and assembly of data: Yüksel Ürün, Syed A. Hussain, Daniel
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